Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9057563rdf:typepubmed:Citationlld:pubmed
pubmed-article:9057563lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:9057563lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:9057563lifeskim:mentionsumls-concept:C0033325lld:lifeskim
pubmed-article:9057563lifeskim:mentionsumls-concept:C0553580lld:lifeskim
pubmed-article:9057563lifeskim:mentionsumls-concept:C0015811lld:lifeskim
pubmed-article:9057563lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:9057563pubmed:issue1lld:pubmed
pubmed-article:9057563pubmed:dateCreated1997-3-27lld:pubmed
pubmed-article:9057563pubmed:abstractTextWe reviewed the treatment outcome of 69 patients with Ewing's sarcoma of the femur. The patients received chemotherapy according to the CESS 81 (n 14), CESS 86 (n 43), and CESS 91P (n 12) protocols. The 10-year relapse-free survival rates were 36%, 65%, and 65% (p = 0.01). 68 patients received local treatment. The primary tumor was treated by surgery without radiotherapy in 28 patients; 1 developed a local recurrence and 7 metastases. 10 patients received radiotherapy alone; 4 developed metastases and 4 local recurrences and metastases. 30 cases had a combination of surgery and radiotherapy; 7 developed metastases and 1 a local recurrence and metastasis. The survival of patients after radiotherapy alone was worse than that of patients after surgery with/without radiotherapy (p = 0.005). Pathological fractures (n 16) did not influence the prognosis.lld:pubmed
pubmed-article:9057563pubmed:languageenglld:pubmed
pubmed-article:9057563pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9057563pubmed:citationSubsetIMlld:pubmed
pubmed-article:9057563pubmed:statusMEDLINElld:pubmed
pubmed-article:9057563pubmed:monthFeblld:pubmed
pubmed-article:9057563pubmed:issn0001-6470lld:pubmed
pubmed-article:9057563pubmed:authorpubmed-author:WinkelmannWWlld:pubmed
pubmed-article:9057563pubmed:authorpubmed-author:OzakiTTlld:pubmed
pubmed-article:9057563pubmed:authorpubmed-author:TreunerJJlld:pubmed
pubmed-article:9057563pubmed:authorpubmed-author:JürgensHHlld:pubmed
pubmed-article:9057563pubmed:authorpubmed-author:HoffmannCClld:pubmed
pubmed-article:9057563pubmed:authorpubmed-author:BlasiusSSlld:pubmed
pubmed-article:9057563pubmed:authorpubmed-author:RübeCClld:pubmed
pubmed-article:9057563pubmed:authorpubmed-author:DunstJJlld:pubmed
pubmed-article:9057563pubmed:authorpubmed-author:Dockhorn-Dwor...lld:pubmed
pubmed-article:9057563pubmed:authorpubmed-author:HillmannAAlld:pubmed
pubmed-article:9057563pubmed:issnTypePrintlld:pubmed
pubmed-article:9057563pubmed:volume68lld:pubmed
pubmed-article:9057563pubmed:ownerNLMlld:pubmed
pubmed-article:9057563pubmed:authorsCompleteYlld:pubmed
pubmed-article:9057563pubmed:pagination20-4lld:pubmed
pubmed-article:9057563pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:9057563pubmed:meshHeadingpubmed-meshheading:9057563-...lld:pubmed
pubmed-article:9057563pubmed:meshHeadingpubmed-meshheading:9057563-...lld:pubmed
pubmed-article:9057563pubmed:meshHeadingpubmed-meshheading:9057563-...lld:pubmed
pubmed-article:9057563pubmed:meshHeadingpubmed-meshheading:9057563-...lld:pubmed
pubmed-article:9057563pubmed:meshHeadingpubmed-meshheading:9057563-...lld:pubmed
pubmed-article:9057563pubmed:meshHeadingpubmed-meshheading:9057563-...lld:pubmed
pubmed-article:9057563pubmed:meshHeadingpubmed-meshheading:9057563-...lld:pubmed
pubmed-article:9057563pubmed:meshHeadingpubmed-meshheading:9057563-...lld:pubmed
pubmed-article:9057563pubmed:meshHeadingpubmed-meshheading:9057563-...lld:pubmed
pubmed-article:9057563pubmed:meshHeadingpubmed-meshheading:9057563-...lld:pubmed
pubmed-article:9057563pubmed:meshHeadingpubmed-meshheading:9057563-...lld:pubmed
pubmed-article:9057563pubmed:meshHeadingpubmed-meshheading:9057563-...lld:pubmed
pubmed-article:9057563pubmed:meshHeadingpubmed-meshheading:9057563-...lld:pubmed
pubmed-article:9057563pubmed:meshHeadingpubmed-meshheading:9057563-...lld:pubmed
pubmed-article:9057563pubmed:meshHeadingpubmed-meshheading:9057563-...lld:pubmed
pubmed-article:9057563pubmed:year1997lld:pubmed
pubmed-article:9057563pubmed:articleTitleEwing's sarcoma of the femur. Prognosis in 69 patients treated by the CESS group.lld:pubmed
pubmed-article:9057563pubmed:affiliationDepartment of Orthopaedics, Westfälische Wilhelms-University, Münster, Germany.lld:pubmed
pubmed-article:9057563pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9057563pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:9057563pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9057563lld:pubmed